Ambiorix1
17 Feb 2016
Biotech rebound today ? Nasdaq Biotech index up 3 days and crossed Nasdaq BiotechIdx SMA 14 yesterday.Ambiorix.
biswell2
17 Feb 2016
Cyprotex Vacancies & Cyprotex USA [link] advertised vacancies , 4 of which are in the USA.A conclusion reading the latest RNS , and new ion channel work to be carried out in the USA in the second half of 2016 might be that the USA turnover is set for a rise.This could also be deduced due to the delayed implementation of the new robotics Tecan screening equipment now being completed.Cyprotex USA can now do most of what Cyprotex UK does , maybe not all because a couple of new machines were installed recently at Alderley Park Labs , but more than 90% I would have thought.The numbers of staff in the USA have also increased and continue to do so.Thus I wonder if Cyprotex might consider selling one of its halves ?For example say if Source BioScience wanted to gain more exposure to the USA where it has been actively expanding its footprint the last 24 months , then the Labs that Cyprotex possess in Boston and Kalamazoo could give it that East coast exposure it lacks.Also Cyprotex has been expanding its new BioSciences DivisionPlus Cyprotex has contracts with nearly 1,000 companies the majority of which Source BioScience does not as they have all but exited from the ADME- Tox arena of Pharma.Plus Cyprotex does business with the Chemical and Cosmetics industries on an increasing scale, businesses and industries that Source BioScience at present does little or none at all with.Expansion of DNA testing/sequencing and other molecular diagnostics services plus installation of new cold room storage facilities within the Cyprotex Labs could quickly follow to add further value.How much is Cyprotex USA worth ?Well I guess that will depend upon the March turnover and profit numbers It surprises me that the same current Institutional holders in both companies have not insisted that both companies enter into a collaboration agreement which should increase sales by a significant amount in both of them , circa 10% I believe.Could a sale of 50% of cyprotex be the reason why ?After the CRX 2016 finals in March I do not think Source BioScience could afford to buy the whole 100%
Carefully Does It
02 Feb 2016
Re: Loan Notes Keep an eye on Instem. Once Tox is done approvals are needed - as efficiently as possible.Watch that space and look at the share register.
Ambiorix1
02 Feb 2016
Re: Loan Notes Nice research Biswell...which confirms my thesis of a consortium led by Christopher Mills holding all the strings, both at Cypro and SBS (and some other similars in this sector). Add to this Henderson is selling all of its holding in Sinclair Pharma to Schroders, and so they have a lot of spare money in the war-chest. Maybe this is the year when they put it all together or take the cash by selling it all together.Ambiorix.
biswell2
02 Feb 2016
Loan Notes Major interests in Loan NotesAt 1 April 2015, the following persons held interests in excess of 3% of the Convertible Loan Notes issued by the CompanyTrident Private Equity Fund III LP 55.27% 2,318,322Alphagen Volantis Catalyst Fund Limited 34.73% 1,456,849Redeemable Loan Notes issued by the Company which total £3.16 million, and are all held by Trident Private Equity Fund III LP.Check out who owns Alphagen Volantis Catalyst Fund[link]
up protherics
22 Jan 2016
Re: Todays news Forgottan to add.. INMO the results will look abysmal as the company will need to set aside any increase in the share price above the 60 pence level during the month of December.If I am correct then this equates to roughly seven million on top of the existing loan of seven million.Currently they have approximately five million in the bank with say a further one to add which on paper in my estimates leaves eight million short. This probably also accounts for yesterdays RNS of no cash bonus which could make the balance sheet look better.So in summaryAnother load of botched RNS announcements and complete lack of understanding as to how the company will never make a profit until the notes are repaid.
up protherics
21 Jan 2016
Just when things become interesting Just when things have become interesting and individual shareholders may benefit,all of a sudden spiv announcements suddenly start to appear.Small questionHas anyone any idea who owns the intellectual property of the new assays which have been developed during the past two years. Cyprotex as a company or the individual scientists who have developed them. This could also explain todays RNS.
up protherics
21 Jan 2016
Todays news A couple of good posts on ADVFN re todays news.I cannot reply to them as I am not a member, but if the posters from ADVFN view iii then this is my response.INMO this is another classic RNS announcement from Cyprotex and whoever is advising themwhat a load of cobs wallop.. I have said all along that ever since they went into this ridiculous loan note arrangement the company would either be taken private ( delisted ) on the cheap then sold at probably ten times the value in a couple of years . Alternatively merged/sold at a cheap level with vested interests from the money lenders they are beholden to.INMO it is now obvious that any takeover will be below 1.20Of course I may be wrong and the directors may be trying to retain cash to pay the money lenders back.We can of course only live in hope,
Carefully Does It
14 Jan 2016
Re: Time for the FCA It was just a normal trading update and they probably had a good view they would be the market expectation but not enough detail to put a figure on it.Look over the dates for previous trading updates. All follows the same pattern.We can expect this type of price behaviour in a low float high growth company with this sort of debt.If in doubt, next time it spikes, sell and move on.I think the company is ethical and this share price behaviour is just the way it is until the loan notes are out of the way. One alternative is updates missing expectations, slaughtering the price and still having debt to pay back.
up protherics
14 Jan 2016
Time for the FCA INMOIt is now time for the FCA to look at the goings on with this company. The events are a replica of two years ago.. The recent RNS announcements are especially dubious together with the content and timing to coincide with the average price before year end for so called accounting purposes.
up protherics
12 Jan 2016
Re: Question Thanks for that.All we now need to know is how much substantially actually means.. Personally I would take that as upwards of 25%.
Ambiorix1
12 Jan 2016
Re: here we go again Hello UpYour house example suits me well to explain you how I see it : in this case major houseowner and the bankowner are probably the same. A consortium around major investor Christopher Mills. They don't mind the loan notes. They control at least 30% of Cypro. It's a win-win, faster and less risky than providing the market with new shares.Your example seems even a good idea to avoid inheritance taxes. Buy a house and ask your kids to provide you the money covered by loan-notes with the same conditions as Cypro. Once your house doubled in price, you pay back the money. No inheritance tax and a great gift for the kids (if they deserve it). (joke).Ambiorix.
Carefully Does It
11 Jan 2016
Re: Question Forecasts that were on Morningstar:[link]
up protherics
11 Jan 2016
Question Are we back to the bad old days of releasing misleading statements with no validity behind them.. For example revenue ahead of market expectations.. What expectations the only expectation I can find is a corporate reiterate with no analysis by the broker.what really concerns me with this is that they still haven't grasped the fact that a p,r exercise with all shareholders would go a long way.
up protherics
11 Jan 2016
Re: here we go again AmbioixWhat is currently happening to the share price happened two years ago. Due to investors not having a clear understanding of the terms of the loan notes.. INMO investors can live with the convertables,but not the loan notes.. Who has ever heard of taking a loan out and should the underlying value of the asset increases the amount of the loan increases as wellFor example you purchase a house worth a 100,000 and take a mortgage with one of the banks of say 50,000.. Five years later the value of the house is 200,000 . You then decide to repay your loan which will probably be around 45,000.However had you borrowed money how Cyprotex has borrowed it under the loan note agreement you would be looking at a repayment value of 100.000 instead of the 45,000.In summary inmo these loan notes will have a detrimental effect on the company and investors unless they are paid off as soon as possibl
